Grifols SA ADR

NASDAQ: GRFS
$6.28
-$0.26 (-4.0%)
Closing price April 19, 2024
Grifols, SA is dedicated to obtaining, manufacturing, preparing and selling therapeutic products, mainly blood derivatives. The company is headquartered in Barcelona, Spain.

Huge Biotech Index Rebalance Means Massive Buy Orders for 5 Stocks
The analysts at Cowen have calculated the buys and sells in the NYSE Arca Biotechnology Index based on the holdings in the First Trust Biotechnology ETF.
Lee Jackson
Published:

Novartis Announces Share Buybacks and Business Expansion
Source: ThinkstockSpeculation has run hot that Swiss drugmaker Novartis A.G. (NYSE: NVS) would announced further restructuring at its investor day in London. Instead, on Friday the company announced...
Trey Thoelcke
Published:

Shire, Novartis Deals: Pharmaceutical Shakeups Continue
Source: ThinkstockThe wave of mergers and acquisitions in health care continues with two big announcements Monday. Drug maker Shire PLC (NASDAQ: SHPG) will acquire the rare disease biopharmaceutical...
Trey Thoelcke
Published:

John Paulson's Big Stock Changes (BAC, C, AEM, AU, COF, GFI, GRFS, JPM, LIFE, NYX, RAH, THC, WFC, GLD, NWSA)
Billionaire and hedge fund manager John Paulson of Paulson & Co. and of Paulson Management is a widely followed equity hedge fund manager for whale watchers.  He has made billions of dollars,...
Jon C. Ogg
Published:
Last Updated: